Podcasts about communicable

Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald return for round 2 taking turns to summarise and discuss late-breaker trials presented at ESCMID Global 2025 in Vienna, and whether or not these trials should change your practice. Part 2 covers the ALABAMA trial exploring the safety of penicillin-allergy delabelling using the penicillin allergy assessment pathway, the SOLARIO trial investigating short (≤7 days!) versus long (≥4 weeks) antibiotic courses for orthopaedic infections, the EAGLE-1 trial assessing oral gepotidacin for gonorrhoea, a randomised clinical trial (RCT) from Thailand on oral fosfomycin as carbapenem-sparing, de-escalating therapy in complicated UTIs, and a double-blind RCT from Israel comparing neutralising plasma to placebo for West Nile fever.    This episode was peer reviewed by Dr. Emanuele Rando of Hospital Universitario Virgen Macarena, Seville, Spain and is the second of this two-part series covering selected clinical trials presented at ESCMID Global 2025.  Late-breaker trialsSandoe J, et al. Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trialAngkanavisan K, et al. Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infection: A randomisedcontrolled trialCanetti M, et al. Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trialDudareva M, et al. Short or long antibiotic regimes in orthopaedics: the SOLARIO multicentre randomised controlled trialWilson, J. Phase 3 randomised trial of oral gepotidacin for the treatment of uncomplicated gonorrhoea (EAGLE-1) ReferencesIDSA. Public Comment: IDSA Guideline on Management and Treatment of Complicated Urinary Tract Infections; 19 Feb - 19 March 2025.Mostashari F, et al. Epidemic West Nile encephalitis, New York, 1999. Lancet. 2001. doi: 10.1016/S0140-6736(01)05480-0Angus DC. Optimizing the Trade-off Between Learning and Doing in a Pandemic. JAMA. 2020. doi: 10.1001/jama.2020.4984Dudareva M. In: The 42nd Annual Meeting of the European Bone & Joint Infection Society. Barcelona, Spain: 26-28 Sept 2024. Li HK, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA). NEJM. 2019 doi: 10.1056/NEJMoa1710926

This episode of Communicable takes on a special format where editors of CMI Comms, Marc Bonten, Josh Davis, Erin McCreary, Emily McDonald, all clinical trialists in their own right, take turns to summarise and discuss late-breaker trials presented at ESCMID Global 2025 in Vienna. These include the CloCeBa trial on Staphylococcus aureus bacteraemia treatment options, the Taper V trial on vancomycin as prophylaxis for Clostridioides difficile infection, the ASTARTÉ trial on temocillin versus meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales, the HARVEST trial investigating high doses of rifampicin for tuberculosis meningitis, and the CAP5 trial on shortening antibiotic treatment for community-acquired pneumonia.   This episode was peer reviewed by Dr. Barbora Píšová (Czech Republic) and is the first of a two-part series covering selected clinical trials presented at ESCMID Global 2025. References: Lescure X, et al. Cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trialMcDonald EG, et al. Initial vancomycin taper for the prevention of recurrent Clostridioides difficile infection: the TAPER-V randomised controlled trialCogliati Dezza F, et al. Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trialVan Crevel R, et al. High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trialBastrup Israelsen S, et al. Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trial

Breakpoints joins forces with CMI Communications' Communicable podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025. Hosts Drs. Erin McCreary and Angela Huttner interview SNAP trial investigators, Drs. Joshua Davis and Steven Tong, on results from penicillin-susceptible and methicillin-susceptible Staphylococcus aureus domains. Conflict of Interest for DSMC Members: Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationship that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner. Each DSMC candidate was well vetted.

In this first-ever collaboration between Communicable and Breakpoints, the podcast of the US Society of Infectious Diseases Pharmacists, hosts Angela Huttner (Geneva, Switzerland) and Erin McCreary (Pittsburgh, USA) join trial investigators Josh Davis (Newcastle, Australia) and Steve Tong (Melbourne, Australia) to unpack the first results coming from the SNAP adaptive platform trial, which were recently presented at ESCMID Global in Vienna. Learn whether penicillin and cefazolin are non-inferior to—and maybe even safer than—flucloxacillin for penicillin-susceptible and methicillin-susceptible Staphylococcus aureus, respectively.This episode was edited by Julie Anne Justo, transcribed by Katie Lambert and Sarah Groom, and peer-reviewed by Megan Klatt and Lacy Worden. Note on conflict of interest for SNAP Data Safety Monitoring Committee (DSMC) members:Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationships that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner. Literature:Steven Y. C. Tong, Joshua S. Davis, Emily Eichenberger et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015 Jul;28(3):603-61.SNAP Adaptive trial platform/results of the PSSA & MSSA domains: https://www.snaptrial.com.au/ESCMID Global April 2025 presentation:www.online.escmid.org *https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/CloCeBa trial results (ESCMID Global April 2025 presentation): www.online.escmid.org *https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/Note on access to online video of ESCMID Global presentations:In the six months following the congress:Non-ESCMID members have access if they registered for ESCMID GlobalMembers have access only if they registered for ESCMID GlobalSix months after the congress:Non-members do not have access, whatever their ESCMID Global registration statusAll members have access, whatever their ESCMID Global registration statusCAMERA 2 trial: Steven Y. C. Tong, David C. Lye, Dafna Yahav, et al. Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA BacteremiaA Randomized Clinical Trial. JAMA. 2020;323(6):527-537. doi:10.1001/jama.2020.0103 POET trial: Kasper Iversen, Nikolaj Ihlemann, Sabine U. Gill et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019;380:415-424POET trial follow-up: Mia M. Pries-Heje, Christoffer Wiingaard, Nikolaj Ihlemann. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial. N Engl J Med 2022;386:601-602

In this episode of Communicable, hosts Angela Huttner and Annie Joseph join experts Kerrigan McCarthy of South Africa's National Institute for Communicable Diseases and Natasha Crowcroft of the World Health Organisation to discuss the resurgence of measles as a consequence of misinformation campaigns and waning vaccination rates, how to diagnose and manage active measles cases, and post-exposure control measures to take to reduce further spread. They also address the broader challenges of the moment, including generalised vaccine hesitancy and sudden, sweeping budget cuts, underscoring the message that “measles anywhere is a problem everywhere.”This episode was edited by Kathryn Hostettler and peer reviewed by Dr. Anelia Zasheva of the Military Medical Academy, Sofia, Bulgaria.

ESCMID Global, ESCMID's flagship congress, kicks off this Friday in Vienna. In light of that, Angela Huttner and Thomas Tängdén sit down with ESCMID leadership, President Robert Skov and Immediate-Past President Annelies Zinkernagel in this episode of Communicable. Together they discuss the roles of medical societies like ESCMID in shaping healthcare policy, the importance of scientific communication, and lessons learned from the COVID pandemic. The conversation highlights ESCMID's priorities for the future on addressing antimicrobial resistance, fostering international collaboration and new educational initiatives. The episode also features personal anecdotes about what makes coming together at ESCMID Global so special. Tune in for a comprehensive look at how ESCMID is championing medical progress in infection for a healthier tomorrow.This episode was edited by Kathryn Hostettler and not peer reviewed.ReferencesGlobal impact of US policy changes: The ESCMID perspective. CMI Comms 2025;2(2): 105073.Malani AN, Sharland M, Clancy CJ, Skov R, ESCMID & IDSA Executive Boards. A global call to action to fight antimicrobial resistance: IDSA and ESCMID joint white paper. CMI Comms 2024; 1(2): 105033.Baghdadi JD & Morgan DJ. Diagnostic tests should be assessed for clinical impact. CMI Comms 2024; 1(2): 105010.

Communicable returns to the topic of gender dynamics in medicine in the second half of this special. This round, Angela Huttner wants to hear from the men, CMI Comms editors Marc Bonten, Josh Davis, Navaneeth Narayanan and Thomas Tängdén, about tackling issues like the evolving expectations at home and work, the impact of parental-leave policies, and the systemic biases that continue to shape careers. Personal anecdotes and reflections highlight both the progress made and the hurdles that still exist in striving for true gender equity in the medical profession. Editors Erin McCreary and Annie Joseph of CMI Comms also participate in the discussion, with Annie sharing an interesting follow-up to her story told in part 1.

Send us a textIn a world filled with uncertainty, it's comforting to know that we serve an unchanging God. "Constant" by Anthony Gargiula, Jordin Sparks, and Maverick City Music reminds us of this powerful truth—God is constant. This episode explores the biblical foundation of God's immutability and how it affects our faith and daily lives.Explore this attribute of God with me and then settle in to a Psalm.In this episode, I discuss:Episode Guide Available: – Download your free Episode Guide at michellenezat.com/512download to help you interact with Scripture.God's Immutability: Unlike humans, who change constantly, God remains the same. His attributes, promises, and purposes never shift.Communicable vs. Incommunicable Attributes: God shares some of His attributes (like love and mercy) with us, but others (like omniscience and immutability) belong to Him alone.Implications of God's Unchanging Nature: Because God is constant, His love, promises, and salvation are secure. We don't have to fear that He will change His mind or go back on His word.Practical Application: How understanding God's immutability can bring peace and stability to our lives.Key Scriptures:Malachi 3:6 - “For I the Lord do not change.”Hebrews 13:8 - “Jesus Christ is the same yesterday and today and forever.”Numbers 23:19 - “God is not man, that he should lie, or a son of man, that he should change his mind.”James 1:17 - “Every good gift and every perfect gift is from above, coming down from the Father of lights, with whom there is no variation or shadow due to change.”Psalm 102:25-28 - A declaration of God's eternal nature.BITEs (Bible Interaction Tool Exercises) Used:Read in contextMake observationsRead in various translationsStudying a topicMeditate on ScriptureCompare and contrastAdditional ResourcesLyrics - New Release TodayDoes God's Immutability Need to Change? - Credo PodcastDoes God Suffer? - Credo PodcastThe Immutability and Impassibility of God - The Gospel Coalition EssayWhat are the communicable and incommunicable attributes of God? - GotQuestions.org ArticleLearn more about my favorite Bible Study Software with a 30-day free trial and links to my all-time favorite Bible resources - Logos Bible Software Affiliate LinkThis Week's ChallengeExamine the Scriptures that declare the immutability of God in their context. (Use the Episode Guide to help.) Malachi 3:6, James 1:17, Hebrews 13:8, Numbers 23:19, Hebrews 6:15-18. Then with all you've learned about God's unchanging nature, head over to Psalm 102 to read in context, make observations, compare and contrast, and meditate. In the end, lift your eyes from your turbulent circumstances to our constant God.Purchase your copy of A Seat at the Table today! Change your music. Change your life. Join my free 30-Day Music Challenge. CLICK HERE.

In honour of International Women's Day, Communicable releases the first of a two-part special on gender dynamics within the fields of infectious diseases and clinical microbiology. Moderated by Angela Huttner, part 1 focuses on the women's perspectives, featuring CMI Comms editors Erin McCreary, Annie Joseph, and Huttner herself, who together reflect on personal experiences of gender bias in the workplace. They discuss differential (mis)treatment, break down common gendered situations in the workplace, and explore what individuals, institutes and society can do to promote a more inclusive, supportive environment for all. Editors Marc Bonten, Josh Davis, Navaneeth Narayanan and Thomas Tängdén of CMI Comms also join for part 1.

There's a good way of wanting to be like God—and a very bad way. Today, Barry Cooper identifies the ways we can, and ought to, imitate God. Read the transcript: https://ligonier.org/podcasts/simply-put/the-communicable-attributes-of-god/ A donor-supported outreach of Ligonier Ministries. Donate: https://donate.ligonier.org/ Explore all of our podcasts: https://www.ligonier.org/podcasts

Several publications have described wondrous therapeutic effects of faecal microbiota transplant (FMT) on Clostridioides difficile infection. Yet the recent randomised trial assessing FMT in US veterans was terminated early for futility. In this episode, hosts Angela Huttner and Marc Bonten delve into the history, application, and complexities of FMT with experts Maria Vehreschild (Frankfurt University Hospital, Germany) and Dimitri Drekonja (Minneapolis Veteran Affairs Care System and University of Minnesota, US), who led the US trial. From the regulatory challenges and trial nuances to important new research, this conversation sheds light on a potentially revolutionary yet controversial treatment. Episode was edited by Kathryn Hostettler and peer-reviewed by Arjana Zerja (Mother Theresa University Hospital Centre, Tirana, Albania).Other mentions:EurFMTEuropean Directorate for the Quality of Medicines & HealthCare. Guide to the quality and safety of tissues and cells for human application. vol. 5th ed. EDQM Council of Europe; 2022. https://freepub.edqm.eu/publications/17/detail LiteratureDrekonja DM et al (2024) Clin Infect Dis, doi: 10.1093/cid/ciae467

Despite being preventable and curable, tuberculosis remains a major global health threat, infecting over 10 million people and claiming more than 1 million lives every year. In this episode of Communicable, hosts Angela Huttner and Navaneeth Narayanan discuss tuberculosis with experts Lorenzo Guglielmetti of Doctors without Borders and Olha Konstantynovska of Kharkiv National University, Ukraine. Key topics include the history, transmission, and pathophysiology of tuberculosis, as well as current diagnostic challenges and treatments for drug-resistant strains. The conversation highlights Lorenzo's work on the endTB project and Olha's experiences managing tuberculosis during the war in Ukraine. Despite advancements in treatment, the episode underscores the urgent need for political will and funding to combat this global health threat.This episode was edited by Kathryn Hostettler and peer reviewed by Dr. Maria Ana de Quadros Flores e Santos of Unidade Local de Saude Santa Maria, Lisbon, Portugal. Abbreviations and terminology used in this episode:MSF: Médecins sans Frontières, or Doctors without Borders (msf.org)FIND: Foundation for Innovative New Diagnostics (www.finddx.org)‘Intoxication symptoms' are synonymous with ‘constitutional symptoms' or ‘B symptoms' of tuberculosis and include fever, night sweats, and unintentional weight loss.  Literature:endTB ProjectAnnual global tuberculosis report by WHO 2024 Dorman SE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021 doi: 10.1056/NEJMoa2033400Guglielmetti L, et al. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med 2025 doi: 10.1056/NEJMoa2400327

God's communicable attributes are those characteristics that He shares with all people made in His image. Today, R.C. Sproul shows how studying these divine attributes can help Christians reflect the holy character of God. Receive R.C. Sproul's book Everyone's a Theologian, his 60-message teaching series Foundations: An Overview of Systematic Theology as a special-edition DVD collection, and lifetime digital access to the messages and study guide, all for your donation of any amount: https://gift.renewingyourmind.org/3887/donate Meet Today's Teacher:   R.C. Sproul (1939–2017) was known for his ability to winsomely and clearly communicate deep, practical truths from God's Word. He was founder of Ligonier Ministries, first minister of preaching and teaching at Saint Andrew's Chapel, first president of Reformation Bible College, and executive editor of Tabletalk magazine.   Meet the Host:   Nathan W. Bingham is vice president of ministry engagement for Ligonier Ministries, executive producer and host of Renewing Your Mind, host of the Ask Ligonier podcast, and a graduate of Presbyterian Theological College in Melbourne, Australia. Nathan joined Ligonier in 2012 and lives in Central Florida with his wife and four children. Renewing Your Mind is a donor-supported outreach of Ligonier Ministries. Explore all of our podcasts: https://www.ligonier.org/podcasts

In this episode Dr. Murphy talks with Claudia Hawkins, MD, Director of the Center for Global Communicable and Emerging Infectious Diseases at the Robert J. Havey, MD Institute for Global Health. She shares her career path from a medical student in the UK to her impactful work in infectious diseases and global health at Northwestern University which includes groundbreaking  HIV and Hepatitis co-infection research.

Sexually transmitted infections (STIs) affect millions globally daily, and multidrug-resistant strains are complicating treatment. Hosts Angela Huttner and Josh Davis welcome experts Dr. Teodora Elvira Wi from WHO and Professor Catriona Bradshaw from Monash University to discuss critical issues surrounding ‘super gonorrhoea,' chlamydia, syphilis, Mycoplasma genitalium, and bacterial vaginosis. The episode reviews the latest epidemiology and highlights the need to innovate diagnostics and treatment options, destigmatise STIs, and promote people-centred healthcare strategies to manage and prevent these infections.  This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Arjana Zerja of Mother Theresa University Hospital Centre, Tirana, Albania.   Literature: Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World Health Organization; 2021. Chris Kenyon et al. on screening impact for gonorrhoea and chlamydia infections in key populations The Lancet HIV 2024.

Exod. 8:8–15 Isa. 40:18–26 Luke 6:32–36 1 Pet. 1:13–21  The doctrine of God is the foundation of all theology. In a very important sense, it is theology. That word “theology” puts two Greek words together and simply means the study or concept of God. In this message, we begin a grand dive into the doctrine of God by learn what the goal of theology is, then two basic categories of God's attributes and how those help us know God.

Rising anti-vaccine sentiment and dissemination of misinformation are threats to public health. In the US, calls to revoke certain public health mandates have been proposed by likely members of the incoming administration, among them vaccination against polio. The fourth instalment of the Nightmare Series is both a cautionary tale and an effort to preserve and share clinical expertise on how to diagnose and manage polio and rubella in a world where, until now, few doctors have had to face these illnesses in the clinical setting. Host Angela Huttner welcomes Professor Emeritus of Infectious Diseases Bernard Hirschel at the University of Geneva and Dr. Kerrigan McCarthy of the Centre for Vaccines and Immunology at South Africa's National Institute for Communicable Diseases (NICD) for that discussion. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Barbora Píšová in Antwerp, Belgium. Literature Link-Gelles R et al (2022) MMWR https://www.cdc.gov/mmwr/volumes/71/wr/mm7133e2.htm  Ryerson AB et al (2022) MMWR https://www.cdc.gov/mmwr/volumes/71/wr/mm7144e2.htm  Kasstan B et al (2023) Epidemiol Infect doi: 10.1017/S0950268823001127 NICD (2024) Report: Rubella in South Africa, 2024.https://www.nicd.ac.za/surge-in-rubella-cases-in-south-africa-november-2024/

The last episode of the year carries a special end-of-year message from the CMI Comms editors and replays the very first episode of Communicable aired on 10 May 2024, in which editors Angela Huttner, Marc Bonten, and Erin McCreary discuss late-breaker clinical trials presented at ESCMID Global 2024 in Barcelona, providing insights into the trials' designs, results, and implications. The DOTS trial compared two doses of long-acting dalbavancin to standard of care in patients with complicated S. aureus bacteraemia. GAME-CHANGER compared cefiderocol to standard of care for Gram-negative infections. PediCAP compared oral step-down therapy with amoxicillin with or without clavulanic acid at shorter durations to the current WHO-recommended standard of five days of intravenous antibiotic therapy in children with severe pneumonia. Additional results from the MULTICAP and CLEEN trials, the CAMERA-2 follow-on in vitro analysis, and the Burkina Faso Escherichia coli transmission study are also discussed. This episode was peer-reviewed by Dr. Yousra Kherabi (Clinical Trials Research Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris; and Université Paris Cité, Inserm, IAME, Paris, France).

Wastewater surveillance is a powerful epidemiological tool that “mirrors our life,” and has gained wide attention in recent years due to its application during the COVID-19 pandemic. The hosts this week, Drs. Navaneeth Narayanan and Emily McDonald, are joined by two wastewater surveillance experts, Dr. Nasreen Hassoun-Kheir of Geneva University Hospitals, a WHO Collaborating Centre on antimicrobial resistance (AMR), as well as Professor David Graham of Newcastle University, United Kingdom, to discuss how this surveillance method—as well as a multidisciplinary approach—are central to understanding community health, infection control and pandemic preparedness. This episode was edited by Kathryn Hostettler and peer reviewed by Dr. James Donnelly of the Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.LiteratureUN Environment Programme (UNEP), Bracing for superbugs (2023) https://www.unep.org/resources/superbugs/environmental-action  Hassoun-Kheir N, et al. EMBRACE-WATERS statement (2021). doi:10.1016/j.onehlt.2021.100339 Hassoun-Kheir N, et al. Systematic review (2020). doi: 10.1016/j.scitotenv.2020.140804 Trask JD, et al. (1942). https://pmc.ncbi.nlm.nih.gov/articles/PMC2135222/Chapters (00:00) - Introduction (03:03) - Icebreaker question (08:33) - What is wastewater surveillance (WWS)? (12:47) - How does WWS relate to infection surveillance? (16:57) - WWS & pandemic preparedness (21:09) - Is the data accessible to the public? (25:10) - WWS uses in healthcare settings & mass health: what it can and cannot answer (43:00) - What's next for WWS: experts' picks (48:33) - Take-home messages

Substandard and falsified (SF) antimicrobials are a neglected global health problem and have been implicated as drivers of antimicrobial resistance (AMR). Substandard medicines are authorized medical products that fail to meet either their quality standards or their specifications, whereas falsified medicines are those that deliberately and fraudulently misrepresent their identity, composition or source. Host Angela Huttner is joined by Pernette Bourdillon Esteve, Technical Officer for the World Health Organization's Substandard/falsified Medical Products group, and Ben Cooper, epidemiologist at Oxford University and head of its Drug-Resistant Infection and Disease Dynamics (DRIaDD), to explore the effects of SF antimicrobials on people and AMR.This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Arjana Zerja of Mother Teresa University Hospital in Tirana, Albania. Literature Cavany S et al.  Nat Commun 14, 6153 (2023). doi: 10.1038/s41467-023-41542-w WHO Global Surveillance and Monitoring System for substandard and falsified medical products (2017). https://www.who.int/publications/i/item/9789241513425 

Send us a textDr. Päivi Sillanaukee, MD, Ph.D. is Special Envoy for Health and Wellbeing, Ministry of Social Affairs and Health Finland ( https://stm.fi/en/rdi-growth-programme-for-health-and-wellbeing ).Dr. Sillanaukee has over 20 years of experience at highest civil servant administrative positions, both from government, including roles as Director General at Ministry of Social Affairs and Health, Ambassador for Health and Wellbeing at the Ministry for Foreign Affairs, as well as various additional roles in the public sector at the Municipalities and Special Health care district levels.Actively participating also in Global Health, Dr. Sillanaukee has chaired and facilitated global multisectoral, multi-partner Health Security collaborations, facilitating capacity building at the country level. She served as Vice chair and member of WHO Executive Board, as Executive President for WHO/Europe Regional Committee, Member of Women in Global Health advocating for Gender Equity in Health, a member of Global Pulse Finland's health sector advisory board, as Member of Board of Directors, Healthcare Information and Management Systems Society (HIMSS) and Member of the Inaugural Board of Digital Health & AI Research Collaborative (I-DAIR).Dr. Sillanaukee has also served as the co-chair of the Alliance for Health Security Cooperation (AHSC) and a member of the Steering Group of the Global Health Security Agenda.Dr. Sillanaukee is skilled in Health Care and Social Affairs management, Health and social service management, Health Security, Universal Health Coverage, Integrated care, Communicable & Noncommunicable diseases, Government, Management, Health Technology & innovation, Entrepreneurship, Quality Management, Interpersonal Skills, Non-profit and for profit Boards. Dr. Sillanaukee graduated with an MD, PhD, and eMBA from University of Tampere, specialization for Public Health Management, and an Honorary Doctor from University of Helsinki Faculty of Medicine.  She also studied humanities and cultural sciences in University of Jyväskylä.#PaiviSillanaukee #Finland #Healthcare #Ambassador #ForeignAffairs #SocialAffairs #HealthSecurity #UniversalHealthCoverage #IntegratedCare #CommunicableDiseases  #Wellbeing  #NoncommunicableDiseases #AgingInPlace #OneHealth #SilverEconomy #HealthTechnology #Entrepreneurship #QualityManagement #HIMSS  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

The market of predatory publishing is as lucrative as it is unethical. Predatory journals are disguised as legitimate entities, and prey on both early-career academics and the naïve. In this episode of Communicable, hosts Angela Huttner and Marc Bonten are joined by Editors-in-chief Ursula Hofer (Lancet Infect Dis) and Leonard Leibovici (CMI) to discuss the various schemes of the ‘Wild West' of publishing, and how to avoid them.  This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Özlem Türkmen Recen, Izmir Public Health Laboratory, Izmir, Türkiye. Literature  Research4Life https://www.research4life.org/  Benedictus R et al. Nature 2016 https://www.nature.com/articles/538453a

Enterococci are commensal microbes, part of the healthy microflora populating the human gut. But they are also opportunistic pathogens and notorious nosocomial agents with intrinsic traits that promote their pathogenesis and make them difficult to kill. In the third instalment of the Nightmare Series, hosts Angela Huttner and Thomas Tängdén are joined by enterococcal experts Kimberly Kline (University of Geneva) and Louis Rice (Brown University) to discuss what make vancomycin-resistant enterococci, or VRE, such a clinical nightmare. Enterococcus faecalis and Enterococcus faecium are the focus. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Nunzia Esposito of the University of Naples Federico II, Naples, Italy. Literature  Stellfox ME et al. J Antimicrob Chemother 14 Feb 2024. doi: 10.1128/mbio.03396-23  Rogers R & Rice LB. Clin Infect Dis 15 Jan 2024. doi: 10.1093/cid/ciad613 Lebreton F et al. Cell 18 May 2017. doi: 10.1016/j.cell.2017.04.027 Donskey CJ et al. N Engl J Med 28 Dec 2000. doi: 10.1056/NEJM200012283432604

Carbapenemase producers are a nightmare for clinicians. Not only are they resistant to carbapenems, a last resort β-lactam antibiotic, they are notorious for developing multidrug and pandrug resistances resulting in limited to no treatment options.  In this episode of Communicable, hosts Angela Huttner and Thomas Tängdén sit down with Dr. David Paterson (National University of Singapore) and Dr. Souha Kanj (American University of Beirut Medical Center, Lebanon), two ID physicians from regions where carbapenem-resistant Enterobacteriaceae or CRE, and carbapenem-resistant Acinetobacter are widespread.  The episode begins with the history and emergence of CRE and reviews current epidemiology, diagnosis (including the Ambler classification of β-lactamases) and treatment options. Lessons and insights from personal experiences are shared to reflect the current clinical challenges caused by carbapenem-resistant bacteria and the importance of infection prevention and control measures to mitigate further spread. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Filippo Medioli of Policlinico di Modena, Italy. For more related content on the WHO Priority Pathogens List and new antibiotics in the pipeline, check out our previous episodes, Communicable E3 and E10 (see Literature).Literature Communicable E3 - The New WHO Priority Pathogens List: which bugs to target first? June 2024. https://communicable.transistor.fm/episodes/communicable-e3-the-new-who-priority-pathogens-list-which-bacteria-to-target-first  Communicable E10 - Pipeline update: new antibiotics & other antimicrobials that you might actually use. Sep 2024. https://communicable.transistor.fm/episodes/communicable-e10-pipeline-update-new-antibiotics-other-antimicrobials-that-you-might-actually-use  Wagenlehner FM, et al. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N Engl J Med 2024 Feb. doi: 10.1056/NEJMoa2304748 Cohn J, et al. Accelerating antibiotic access and stewardship: a new model to safeguard public health. Lancet Infect Dis 2024 Sep. doi:  10.1016/S1473-3099(24)00070-7 Timsit JF, et al. When should I start broad-spectrum antibiotics? Intensive Care Med 2024 Sep. doi: 10.1007/s00134-024-07654-7  Paterson DL. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 2024 Apr. doi: 10.1080/13543784.2024.2326028 

On the verge of a post-antibiotic reality, there is an urgent clinical need for new antibiotics. Luckily, new candidates are in the pipeline and older agents are getting a second breath of life through combination therapy.  In this episode of Communicable, host Erin McCreary invites Dr. Markus Zeitlinger of the University of Vienna (Austria) and scientific expert for the European Medicines Agency (EMA) and Dr. Michael Dudley, president and CEO of Qpex Biopharma, to discuss antimicrobials in the clinical development pipeline.  Together they unpack how the WHO curate the priority list of pathogens and how companies adapt such lists into their antimicrobial development business plans. They also discuss the unique challenges and complexities of developing antibiotics, from return on investments and defining the ‘novelty' of an agent to the conundrum of balancing post-market approval and antimicrobial stewardship. Beta-lactamase inhibitors and oral carbapenems in the pipeline targeting ‘the big three' (Enterobacterales, Pseudomonas and Acinetobacter) are the primary focus. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Benjamin Berinson of the Medical Centre Hamburg-Eppendorf (UKE), Germany. For more information on the WHO Priority Pathogens List and its 2024 update, check out our previous episode, Communicable E3 (see Literature).  Literature  Communicable E3 - The New WHO Priority Pathogens List: which bugs to target first? 17 June 2024. https://communicable.transistor.fm/episodes/communicable-e3-the-new-who-priority-pathogens-list-which-bacteria-to-target-first  WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 17 May 2024. https://www.who.int/publications/i/item/9789240093461  C. Le Terrier et al, NDM-9 resistance to taniborbactam. Lancet Infect Dis 23, 401-402 (2023). doi 10.1016/S1473-3099(23)00069-5      P. B. Eckburg et al, Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 386, 1327-1338 (2022). doi: 10.1056/NEJMoa2105462  A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO). https://clinicaltrials.gov/study/NCT06059846 Meiji Seika Pharma Initiated the Global Phase III Clinical Trials of OP0595, a Novel beta-Lactamase Inhibitor for Combatting Antimicrobial Resistance (AMR). Tokyo: Meiji Seika Pharma Ltd; 26 April 2023. https://www.meiji.com/global/news/2023/pdf/230426_01.pdf

The current H5N1 avian flu outbreak in poultry and dairy cows in the US has raised the alarm on bird flu and its transmission risk across species. At present, the virus has infected 100 million birds across 48 states and 196 dairy herds across 14 states. Luckily, the H5N1 avian flu, which is very lethal in birds, does not transmit easily into humans nor does it generally cause severe and systemic symptoms when humans are infected. Still, workers most exposed to these infected animals are testing positive with 14 human cases reported so far since 2022. In this Communicable episode, hosts Angela and Nav are joined by avian flu expert Ron Fouchier (Erasmus MC Rotterdam, Netherlands) to discuss the most recent developments of the outbreak in the US and the potential risks H5N1 virus poses to humans. Understanding of the virus from its first reported outbreak in Hong Kong in 1997 to its global prevalence today is reviewed. While H5N1 bird flu does not pose as a global human health concern at present, unchecked practices in the dairy, meat, and agricultural industry sectors, in which workers are exposed to the virus, threaten to change the status quo. Learn why the threat is even more paramount in fall when human influenza or seasonal flu is widespread, and to what extent the government should also be involved in prevention and containment measures before it becomes, in Ron's words, another “missed opportunity.”          This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Simon Galmiche of the Institut Pasteur, Université Paris Cité, Paris, France.LiteratureUS Centers for Disease Control and Prevention (CDC). H5 Bird Flu: Current Situation. 2024. https://www.cdc.gov/bird-flu/situation-summary 

Only known to us since 2008, Candida auris is an emerging fungal pathogen spreading quickly around the world; alarmingly, it is most commonly found in healthcare settings. C. auris sets itself apart from other Candida species with its unique tolerance to high saline and temperature environments and propensity to develop antifungal resistances that promote its survival in hospitals and healthcare facilities. Hosts Emily McDonald and Navaneeth Narayanan are joined by fungal experts Dr. Jeffrey Rybak (St. Jude, Memphis TN) and Dr. Graham Snyder (UPMC, Pittsburgh PA) on their quest to better understand C. auris infections, the clinical challenges and knowledge gaps in C. auris research and discuss measures for prevention and containment on the levels of both the patient and the institution. The recent emergence of C. auris as a multidrug-resistant nosocomial pathogen and its global prevalence has raised more questions than answers. Why now? Why healthcare facilities? Does climate change play a role? Are humans to blame? Tune in to find out what the experts have to say on these questions, and stay to learn about the current therapies available, what is in the antifungal pipeline and how to approach treatment from a stewardship standpoint.This episode was produced by Angela Huttner, edited by Kathryn Hostettler and peer-reviewed by Dr. Claudio Neidhöfer of University Hospital Bonn, Germany.LiteratureSatoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009 Jan;53(1):41-4. doi: 10.1111/j.1348-0421.2008.00083.xLee WG, Shin JH, Uh Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011 Sep;49(9):3139-42. doi: 10.1128/JCM.00319-11Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016. OFID. 2019 March;6(S1): S79–S94. doi: 10.1093/ofid/ofy358Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017 Jan 15;64(2):134-140. doi: 10.1093/cid/ciw691.Clancy CJ, Nguyen MH. Emergence of Candida auris: An International Call to Arms. Clin Infect Dis. 2017 Jan 15;64(2):141-143. doi: 10.1093/cid/ciw696Rybak JM, Cuomo CA, Rogers PD. The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris. Curr Opin Microbiol. 2022 Dec;70:102208. doi: 10.1016/j.mib.2022.102208 

Once considered endemic only to tropical and subtropical climates such as Southeast Asia and northern Australia, melioidosis is expanding to non-endemic areas such as the southern US. Climate change is impacting infectious diseases, melioidosis being no exception. Now is the time to inform and prepare: as this Communicable episode's title indicates, melioidosis is going global.Join hosts Angela Huttner and Josh Davis on their in-depth exploration of melioidosis with invited experts Dr. Ella Meumann and Prof. Bart Currie from Royal Darwin Hospital, Darwin, Australia. Topics range from melioidosis discovery, clinical presentation, diagnostic approaches and host risk factors to the disease's expanding endemicity.Melioidosis is an infectious disease caused by the sapronotic agent Burkholderia pseudomallei and contracted by both people and animals through direct contact with contaminated soil, air or waters. Current burden estimates of 169'000 cases and 89'000 deaths per year are thought to be grossly underreported due to limited access to laboratory diagnostics and lack of clinical awareness. Experts call for melioidosis to be recognized as a neglected tropical disease in order to give this disease the urgent attention and resources it deserves.This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Goulia Ohan of Yerevan State Medical University, Armenia.Literature Meumann EM and Currie BJ. Approach to melioidosis. CMI Comms 2024;1(1). doi: 10.1016/j.cmicom.2024.100008 Savelkoel J, Dance D. Alfred Whitmore and the Discovery of Melioidosis. Emerg Infect Dis. 2024;30(4):752-756. doi:10.3201/eid3004.230693 Limmathurotsakul D, Wongsuvan G, Aanensen D et al. Melioidosis Caused by Burkholderia pseudomallei in Drinking Water, Thailand, 2012. Emerg Infect Dis. 2014;20(2):265-268. doi: 10.3201/eid2002.121891 Petras JK, Elrod MG, Ty MC, et al. Locally acquired melioidosis linked to environment—Mississippi, 2020-2023. N Engl J Med. 2023;389:2355-2362. doi: 10.1056/NEJMoa2306448Howes M and Currie BJ. Melioidosis and Activation from Latency: The “Time Bomb” Has Not Occurred. ASTMH. 28 May 2024;111(1): 156-160. doi 10.4269/ajtmh.24-0007

Responsible for 1.3 million deaths and 2.2 million new infections per year, viral hepatitis is the second leading cause of morbidity and mortality amongst all infectious diseases, just behind tuberculosis.  Hosts Angela Huttner and Oana Sandulescu welcome special guest and leading hepatitis expert, Professor Mojca Matičič, MD, PhD (Ljubljana, Slovenia), to refresh your knowledge on the pathogenesis of hepatitis B & C infections, review the latest direct-acting antiviral (DAA) therapies, map out some countries' successful elimination initiatives, and understand challenges remaining for others. In recognition of World Hepatitis Day this Sunday, 28 July, a day dedicated to raising awareness about viral hepatitis, we are releasing our latest episode a few days early. The World Hepatitis Day theme this year is: it's time for action! The Communicable team urges our listeners to inform themselves and others, and to test, treat, and vaccinate against viral hepatitis.  This episode was peer reviewed by Dr. Liem Luong of CIC Cochin Pasteur, Hôpital Cochin-Port Royal, Assistance Publique-Hôpitaux de Paris, Paris, France. LiteratureWorld Hepatitis Day 2024: It's time for action. Geneva: World Health Organization; 2024. https://www.who.int/campaigns/world-hepatitis-day/2024 Method for global reporting on disease burden and service coverage data for viral hepatitis B and C, 2022. In: Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. doi: 10.2471/B09024. The European Association of the Study of the Liver (EASL). EASL Congress Milan, Italy 5-8 June 2024. https://www.easlcongress.eu/European Centre for Disease Prevention and Control (ECDC). ECDC Evidence brief: Prevention of hepatitis B and C in the EU/EEA. Stockholm: ECDC; 2024.  European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC; 2024.  Burnet Institute and Kirby Institute. Australia's progress towards hepatitis C elimination: annual report 2022. Melbourne: Burnet Institute; 2022. Maticic M, Pirnat Z, Leicht A, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020 Nov 19;17(1):89. doi: 10.1186/s12954-020-00439-3.

Morning: Third Day Morning: God Creator and Controller: https://banneroftruth.org/us/devotional/third-day-morning-god-creator-and-controller/ Spurgeon's Morning and Evening, July 16, Morning:  https://www.biblegateway.com/devotionals/morning-and-evening/2024/07/16 1 Kings 22: https://read.lsbible.org/?q=1+Kings+22 2 Chronicles 18: https://read.lsbible.org/?q=2+Chronicles+18 Matthew 2: https://read.lsbible.org/?q=Matthew+2 Conflict (182) Evening: Peril (184) Glorifying God, Thomas Watson, July 16 Message: Certainties Of The Word Of Life, The Word Of Life Is Communicable, 1 John 1:2b-3a Third Day Evening: Before Sleep: https://banneroftruth.org/us/devotional/third-day-evening-before-sleep/ Resources: Valley of Vision: https://banneroftruth.org/us/store/devotional-books/the-valley-of-vision/ Spurgeon's Morning and Evening: https://www.amazon.com/Morning-Evening-Classic-Daily-Devotional/dp/1683227247/ref=pd_lpo_1?pd_rd_i=1683227247&psc=1 Legacy Standard Bible: https://316publishing.com/ Glorifying God, Thomas Watson: https://www.amazon.com/Glorifying-God-Inspirational-Messages-Thomas/dp/140418712X/ref=tmm_hrd_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.RxmikVPx1TbCsaSCjkzxXvQu3AKtIrHMzUnVuUojQXDf94C0nKibszGVgpGBwttw2fMNOjz4KCLQtgLkdNcXCQ.m9etrS0_7bNsGcyvw3NtwysBMrVzvuUG8XBRpIRXH7E&qid=1708794474&sr=8-1 At The Throne Of Grace, John MacArthur: https://www.gty.org/store/books/451172 2024 Reading Plan(5 day): https://www.fivedaybiblereading.com/wp-content/uploads/2023/12/2024-Five-Day-Sked-bw-Large-Print.pdf Vail Valley Baptist Church GiveSendGo Campaign Link: https://www.givesendgo.com/vvbc-az-school --- Support this podcast: https://podcasters.spotify.com/pod/show/wayne-floyd/support

The ‘I' (intermediate susceptibility) in a EUCAST-guided antibiogram never meant impending resistance to your antibiotic. It was never meant to make you find the one ‘S' (invariably a carbapenem) and use it instead—even if many clinicians did. In this episode of Communicable, hosts Marc Bonten and Angela Huttner welcome Profs. Christian Giske (outgoing chair) and Sören Gatermann (newly elected chair) of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) to discuss its recent updates, including the new ‘susceptible dose dependent' (SDD) label, and to shed light on common misconceptions around the way it sets breakpoints. Breakpoints for Pseudomonas aeruginosa are discussed, as are intravenous fosfomycin's ‘disappearance' from the breakpoints table and EUCAST's new guidance on it. Episode peer-reviewed by Dr. Suzanne van Asten of Radboud University Medical Center.Literature:The European Committee on Antimicrobial Susceptibility Testing (EUCAST): https://www.eucast.org/EUCAST guidance on use of fosfomycin i.v. breakpoints:https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Use_of_fosfomycin_iv_breakpoints_General_advice_20240528.pdfIn vitro synergy between fosfomycin and ceftazidime/avibactam: Kroemer, Martens, Decousser et al. Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in Escherichia coli. J Antimicrob Chemother. 2023 Oct 3;78(10):2524-2534. doi: 10.1093/jac/dkad264

Hosts Angela Huttner & Erin McCreary welcome Prof. David Paterson (Singapore) and Prof. Josh Davis (Newcastle, Australia) to discuss the design and results of the BLING-3 trial, which compared continuous infusion of beta-lactam antibiotics to standard intermittent dosing in 7000 critically ill patients across 104 intensive-care units. In unadjusted analyses, the trial did not show a statistically significant mortality benefit with continuous infusion. Yet in prespecified adjusted analyses, there was a statistically significant reduction in mortality, and a meta-analysis of randomized trials published simultaneously with the BLING-3 trial showed the same. As the two ID doctors on the BLING team, Profs. Paterson and Davis offer context and insights into what these results mean and how they might affect your clinical practice. Episode peer-reviewed by Dr. Mia Lidén of Charité – Universitätsmedizin Berlin.  LiteratureBLING-1: Dulhunty et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013 Jan;56(2):236-44. DOI: 10.1093/cid/cis856BLING-2: Dulhunty et al. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1298-305. DOI: 10.1164/rccm.201505-0857OCBLING-3: Dulhunty et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024 Jun 12:e249779.DOI: 10.1001/jama.2024.9779Meta-analysis: Abdul-Aziz et al. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA. 2024 Jun 12:e249803. DOI: 10.1001/jama.2024.9803

What are WHO's most wanted bacterial pathogens in 2024? Hosts Angela Huttner & Oana Sandulescu welcome guests Dr. Hatim Sati of the World Health Organisation (WHO) and Dr. Erin Duffy (CARB-X) to discuss WHO's new Priority Pathogens List. Developed by WHO and a panel of global experts, the List identifies the ‘top' bacteria for which research & development are of critical, high, and medium priority, and thus serves as a framework for resource allocation and public-policy guidance. Episode peer-reviewed by Dr. Galadriel Pellejero of Lozano Blesa Clinical Hospital, Zaragoza, Spain. Literature:WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance.https://www.who.int/publications/i/item/9789240093461

Puntata 515: Valeria ci parla dei casi di influenza aviaria H5N1 documentati di recente negli Stati Uniti  nelle mucche e negli umani. Nonostante le mucche non siano un ospite abituale dei virus influenzali, negli Stati Uniti si sono riportate infezioni da parte di questo virus in molti paesi diversi che tuttavia non interessano il tratto respiratorio ma le mammelle. Questo virus sembra essere in grado di essere trasmesso da mucca a mucca nonostante non siano ancora chiare le modalità. Sono anche stati registrati 3 casi umani di persone a diretto contatto con le mucche, che hanno mostrato come sintomo principale la congiuntivite. La situazione va monitorata in quanto dobbiamo prevenire un adattamento del virus all'uomo e il passaggio del virus da uomo a uomo. Tuttavia dobbiamo ricordare che, sulla carta, rispetto al covid siamo in una situazione migliore sotto diversi aspetti. In esterna, in differita dal Mantova Food&Science Festival, Simone intervista uno Stefano Bertacchi selvatico sulle TEA, le tecnologie di evoluzione assistita. Stefano è un biotecnologo, ricercatore e divulgatore scientifico. E' autore di 4 libri e colleziona pokemon.Dopo la barza Marco continua a parlare di palle di cose strane, in questo caso le gluebal, palle di gluoni, le controparti del fotone per la forza nucleare forte.Per approfondire:https://www.nejm.org/doi/full/10.1056/NEJMc2405495https://www.nejm.org/doi/full/10.1056/NEJMc2405371https://www.cdc.gov/flu/avianflu/avian-flu-summary.htmhttps://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-week-22-2024.pdfDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/scientificast--1762253/support.

In this episode, hosts Josh Davis (Newcastle, Australia) and Angela Huttner (Geneva, Switzerland) interview the phage ‘microbiologist-clinician duo', Drs. Shawna McCallin and Lorenz Leitner (Balgrist Hospital, Zurich, Switzerland). They explore the history of phages, the process of bringing phage therapy to a patient, potential resistance to phages, availability of individualized therapy versus phage cocktails, and the place of phage therapy in the future. Drs. Leitner and McCallin reflect on the challenges and lessons of their recently published randomized trial comparing phage therapy to antibiotics for urinary tract infection. Episode peer-reviewed by Dr. Olivia Funk of Long Island University. LiteratureLeitner L, Ujmajuridze A, Chanishvili N et al.  Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021 Mar;21(3):427-436. doi: 10.1016/S1473-3099(20)30330-3. 

In this episode, Pastor Jeremy Wilbanks discusses the moral or communicable attributes of God. These attributes allow God to communicate and connect with humanity on a personal level, unlike the natural or incommunicable attributes that belong to God alone.

Warning: This interview contains graphic descriptions of violence and death.Throughout the past five and a half months, Israel has waged a full-spectrum war against the civilian population of the Gaza Strip. The United States and other Western nations have supplied not only the weapons for this war of annihilation against the Palestinians, but also key political and diplomatic support.The results of the actions of this coalition of the killing have been devastating. Conservative estimates hold that more than 31,000 Palestinians have been killed, including 13,000 children. More than 8,000 people remain missing, many of them believed to have died in the rubble of buildings destroyed in Israeli attacks. Famine conditions are now present in large swaths of the Gaza Strip. For months, doctors across Gaza have performed amputations and other high-risk procedures without anesthetics or proper operating rooms. Antibiotics are in short supply and often unavailable. Communicable diseases are spreading, as hundreds of thousands of Palestinians are forced to live in makeshift shelters with little access to toilets or basic sanitary supplies. Israel has repeatedly blocked or delayed aid shipments of vital medical supplies to Gaza. Basic preventative medical care is nearly nonexistent, and medical experts predict that malnutrition will condemn a new generation of young Palestinians to a life of developmental struggles. The result of the onslaught against medical facilities is that there is only one fully functional hospital remaining in the territory, the European Hospital in Khan Younis. Dr. Yasser Khan, a Canadian ophthalmologist and plastic surgeon, just left Gaza where he spent 10 days at the hospital performing eye surgeries on victims of Israeli attacks. It was his second medical mission to Gaza since the war began last October. On this special Intercepted, Dr. Khan speaks to Jeremy Scahill about what he witnessed. If you'd like to support our work, go to theintercept.com/join, where your donation, no matter what the amount, makes a real difference.And if you haven't already, please subscribe to the show so you can hear it every week. And please go and leave us a rating or a review — it helps people find the show. If you want to give us additional feedback, email us at Podcasts@theintercept.com. Hosted on Acast. See acast.com/privacy for more information.

Dan Roeber and Mike Shockey chat about specific attributes we're called to emulate as believers.

23 hour plane rides. Communicable diseases. Wrong side of the road mishaps. From Hawaii to Cancun to Thailand, from hurricanes to Hershey squirts, when gigging out of town, anything can happen, and usually does. Credit Of The Week Link: https://on.soundcloud.com/DrK3E

Andy Baker White, ASTHO's Senior Director of State Health Policy, outlines three new policy recommendations on Public Health Legal Authority; Dr. Georgina Peacock, the Director of the Immunization Services Division in the National Center for Immunization and Respiratory Diseases at the CDC, says vaccine coverage among kindergarten children is at a decade low; an ASTHO blog explains how Rhode Island was able to add 28 permanent staff positions; and sign up for ASTHO's Public Health Weekly email newsletters.   ASTHO Webpage: Public Health Legal Authority to Prevent and Mitigate the Spread of Communicable and Infectious Diseases and Other Public Health Threats CDC: Back to School with Routine Vaccines ASTHO Webpage: Workforce Policy Spotlight: Successfully Raising FTE Caps in Rhode Island ASTHO Webpage: Public Health Weekly email newsletters

In this episode hosts Oren Martin and Caitlin Van Wagoner talk to guest John Elmore about who God the Father is, what He is like, and why it matters. Part I: (02:36 - 04:48)Why does it matter to know what God is like? Imago Dei Incommunicable and communicable attributes of God Scripture Mentioned: Acts 17:22-31 Part II: (04:48 - 16:29)How can't we be like God? Incommunicable (or inscrutable) attributes of God: qualities that God alone possesses Scripture Mentioned: Psalm 139:4, Romans 1-8, Romans 11: 33-36, Psalm 90:2, Genesis 1, Ephesians 1:4 Part III: (16:29 - 26:42)How can we be like God? Communicable attributes of God: qualities that we can share with Him, in finite ways Common Grace Scripture Mentioned: John 14, 1 John, Leviticus 19:2, Romans 1:8, Acts 17 Part IV: (26:42 - 32:25)Which attribute of God is most important?re:generationScripture Mentioned: John 14:6 Part V: (32:25 - 35:00What is God not like?The Great CommissionScripture Mentioned: Matthew 28:16-20 __ Learn more about Watermark Community Church at watermark.org Follow along with WatermarkInstagram | YouTube | Facebook | Twitter

What are the communicable attributes of God? What are the incommunicable attributes of God?

Welcome to summer, my friends! This month, we'll be talking about how to engage who we are on the inside so we can better connect with God, get to know who He has always been, and walk with Him from a more authentic place. Once we can do that, it spills over into our relationships around us. Past me would think it was completely crazy to pursue space for growing myself in the summer but present me says that this part of our story matters. We've got self-examination, growth, and care to do. God has much to show us and heal in us. Are you willing to come along for the ride? Today we'll start with Meredith Boggs. Meredith is a podcaster and an author. Her book The Journey Home: A Biblical Guide to Using the Enneagram to Deepen Your Faith and Relationships tells the story of her life as a young adult and doing all the good Christian things, but finding herself burned out and confused. Looking for a way to breathe life back into her soul and her faith and the Enneagram became a tool that God used to minister to her.  Ohhhh the Enneagram: We're going to talk about the beef people have with it, the understandable concerns many have about it, the misuse of it, AND if it is a useful tool to you, then how could we see what God has for people of faith in it so they can grow into who God made them to be. Maybe you've never even heard of it or only heard weird things about it OR you're over it. Give us another chance today because how Meredith breaks down perspectives about how the enneagram can be used well and not well in relationships, and how it can build one another up in the body of Christ is really beautiful and unique. Of all the Enneagram content I've consumed over the years, Meredith's voice has become my favorite. Her book is about spiritual growth more than a personality evaluation. It is grace-filled, but honest and nuanced. I loved this conversation with her so much where you will get to hear some of Meredith's story and hear her share about her journey with recognizing weaknesses and surrendering in recovery and learning how to trust God in those places.   I hope that this conversation ministers to you today. If anything, I hope you hear that we are ALL in progress. We all have weaknesses and limits and the Lord can and will make Himself known in all of them. Transformation takes time, it is messy, and grappling with who God really versus how broken people sometimes claim Him to be can be an adventure, but a worthwhile one.  You matter, and your story matters. Connecting with Meredith: Book: The Journey Home: A Biblical Guide to Using the Enneagram to Deepen Your Faith and Relationships Facebook Instagram Podcast TikTok Website Episode Sponsor: Tony Crabtree of Crabtree Homes with Exit Realty Facebook Instagram  Tik Tok  Website YouTube References: Enneagram  The Road Back to You Enneagram 8  Enneagram Test (a free one) Enneagram Test from Enneagram Institute (paid one!) Ian Morgan Cron  Annie F. Downs' Enneasummer series  Myers Briggs Strengths Finder Enneagram 7 Enneagram 3 Beth McCord Harry Potter (y'all know I'm a #Potterhead), the beef with it when the books were coming out “Hocus Pocus 2” Enneagram 2 Codependency (more words about this here and here) John Calvin quote- “Without knowledge of self there is no knowledge of God Our wisdom, in so far as it ought to be deemed true and solid Wisdom, consists almost entirely of two parts: the knowledge of God and of ourselves. But as these are connected together by many ties, it is not easy to determine which of the two precedes and gives birth to the other.” Our friend Kelsey is Kelsey Chapman. You can hear my conversation with her on episode 73  Triads Attributes of God Daily Grace Co. study (Affiliate link, thank you for your support!) Communicable vs. incommunicable attributes of God  Walking in the Spirit Aslan who creates (From Magician's Nephew by C.S. Lewis) 12-Step Recovery Process The Power to Choose Meredith's resources on her website   Scripture References: Galatians 5:22-23- Fruit of the Spirit 1 Corinthians 12:12-27- How the body of Christ functions (all its unique parts) Lamentations 3:40-  see ourselves rightly Luke 10:27; Matthew 22:36–40; Mark 12:28–31-Love the Lord with all your heart, mind, soul, and strength, and love your neighbor as yourself Psalm 90:12- Grant me a heart of wisdom  Ephesians 1:18- Enlighten the eyes of my heart Isaiah 9:7- God's power has no end and He has no limits 2 Corinthians 12:9-11- In my limits/weaknesses, He is strong Ephesians 3:20- Even more, than we could ask or imagine  Jeremiah 29:11, Romans 8:28- He has a purpose for you  Isaiah 63:7- God is kind to us  Psalm 27:13-God is good  (just one scripture!) 1 Corinthians 3:9- We are co-creators with God Philippians 1:6- He will complete the work He began in us Philippians 4:19-God does provide for all of our needs   JOIN OUR PATREON COMMUNITY!!!! I would be honored to have your support to keep the Simply Stories Podcast going. You can sign up for as little as $3 a month and each tier offers gifts that I hope will bless you in return.    Connecting with Emily and Simply Stories Podcast: Instagram (Em life // Podcast Life) Facebook Twitter Blog   

God's communicable attributes are those characteristics that He shares with all people made in His image. Today, R.C. Sproul shows how studying these divine attributes can help Christians reflect the holy character of God. Get the 'Foundations: An Overview of Systematic Theology' DVD Series for Your Gift of Any Amount: https://gift.renewingyourmind.org/2381/foundations Don't forget to make RenewingYourMind.org your home for daily in-depth Bible study and Christian resources.

Jen Wilkin, JT English, and Kyle Worley discuss and define the communicable attributes of God.Questions Covered in This Episode:What are communicable attributes?Are the communicable attributes one of the ways we reflect the image of God?Are communicable attributes something God is or something God possesses?Are communicable attributes true of each person in the Godhead?How are they different from incommunicable attributes (what we discussed last episode)?How do we maintain a distinction between Creator and creature without minimizing the reality and depth of the shared communicable attributes?Helpful Definitions:Attribute: Something that is true about God, who he is.Communicable Attribute: Things that are true about God, that can also become true of us.Holy, loving, just, good, merciful, gracious, faithful, patient, truthful, wiseAnthropomorphic: A way of expressing, in humanly understandable terms, something that is true.Resources Mentioned in This Episode:John 3:16, 1 John 5:3“In His Image” by Jen WilkinKnowing Faith: Episode # 158 – What is God like? Incommunicable Attributes“Creation Regained” by Albert WoltersAmazon affiliate links are used where appropriate. As an Amazon Associate we earn from qualifying purchases, thank you for supporting Knowing Faith.Sponsors:Discover how Midwestern Seminary can equip you to more faithfully serve your church through formal theological education or FREE For the Church resources we provide: mbts.edu/KnowingFaithOur Sister Podcasts:The Family Discipleship Podcast | Confronting ChristianitySupport Training the Church and Become a Patron:patreon.com/trainingthechurch

There's a good way of wanting to be like God--and a very bad way. In this episode, Barry Cooper identifies the ways we can, and ought to, imitate God. Read the transcript: https://simplyputpodcast.com/the-communicable-attributes-of-god/